Zobrazeno 1 - 10
of 485
pro vyhledávání: '"Holen I"'
Autor:
Porter, I., Theodoulou, E., Holen, I., Harper-Wynne, C., Baron-Hay, S., Wilson, C., Brown, J.
Publikováno v:
In Journal of Bone Oncology December 2021 31
Autor:
Hadji, P., Coleman, R.E. *, Wilson, C., Powles, T.J., Clézardin, P., Aapro, M., Costa, L., Body, J.-J., Markopoulos, C., Santini, D., Diel, I., Di Leo, A., Cameron, D., Dodwell, D., Smith, I., Gnant, M., Gray, R., Harbeck, N., Thurlimann, B., Untch, M., Cortes, J., Martin, M., Albert, U.-S., Conte, P.-F., Ejlertsen, B., Bergh, J., Kaufmann, M., Holen, I.
Publikováno v:
In Annals of Oncology March 2016 27(3):379-390
Publikováno v:
In The Breast 1 August 2013 22 Supplement 2:S50-S56
Publikováno v:
In Journal of Bone Oncology September 2012 1(2):47-56
Mechanically dependent processes are essential in cancer metastases. However, reliable mechanical characterization of metastatic cancer remains challenging whilst maintaining the tissue complexity and an intact sample. Using atomic force microscopy,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::c0d25c7402685bf8eba604f1e4226c23
https://eprints.whiterose.ac.uk/184636/1/d1nr03900h.pdf
https://eprints.whiterose.ac.uk/184636/1/d1nr03900h.pdf
Publikováno v:
Cancers
Metastatic recurrence, the major cause of breast cancer mortality, is driven by reactivation of dormant disseminated tumour cells that are defined by mitotic quiescence and chemoresistance. The molecular mechanisms underpinning mitotic quiescence in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::6a80b4eae1a46b3bfcf0a2a8da03e7aa
https://eprints.whiterose.ac.uk/177934/1/cancers-13-03922.pdf
https://eprints.whiterose.ac.uk/177934/1/cancers-13-03922.pdf
Autor:
Hughes, R., Chen, X., Cowley, N., Ottewell, P.D., Hawkins, R.J., Hunter, K.D., Hobbs, J.K., Brown, N.J., Holen, I.
Metastatic breast cancer in bone is incurable and there is an urgent need to develop new therapeutic approaches to improve survival. Key to this is understanding the mechanisms governing cancer cell survival and growth in bone, which involves interpl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::495ea412cbb9c4cf6fb341b108fec2d4
https://eprints.whiterose.ac.uk/172566/1/cancers-13-01366.pdf
https://eprints.whiterose.ac.uk/172566/1/cancers-13-01366.pdf
Background: Breast cancer (BC) is one of the leading causes of cancer-related deaths worldwide. Standard therapies aim to disrupt pathways that regulate the growth and survival of BC cells. Therapeutic agents such as endocrine therapy target hormone
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::8d4fbed5dcc665a26ee296e07dec0599
Zoledronic acid (ZOL) is an antiresorptive drug used to prevent bone loss in a variety of conditions, acting mainly through suppression of osteoclast activity. There is growing evidence that ZOL can also affect cells of the mesenchymal lineage in bon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::41249516f08e3f0427d82ff1135eaf6f
Background: Bone metastasis is one of the most common complications of advanced breast cancer. During dissemination to bone, breast cancer cells locate in a putative ‘metastatic niche’, a microenvironment that regulates the colonisation, maintena
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::078528f6993b788c279b659e1c53fd9a